illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Fagron
Company logo

Fagron | Sustainability Performance

https://www.fagron.com

Fagron NV specializes in pharmaceutical products and compounding services. The company aims to provide tailored medications that meet specific patient needs while maintaining compliance with regulatory standards.

1990

Belgium

1,001 - 5,000 employees

Pharmaceuticals

$1B - 10B in revenue

$100M - 500M in profitability

Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.

Sustainability Ranking & Industry Benchmark

#3849
Overallⓘ
#48
in Belgiumⓘ
#90
in Pharmaceuticalsⓘ

Sustainability Maturity

ⓘ
​​0123456789​​%

Sustainability Intent

ⓘ

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

29 out of 292

Overview
Environmental
Energy consumption
Governance
Targets
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
Union Chimique Belge (UCB)

Belgium, Health Care, Pharmaceuticals


Company logo
Industri Jamu Dan Farmasi Sido Muncul

Indonesia, Health Care, Pharmaceuticals


Company logo
RPG Life Sciences

India, Health Care, Pharmaceuticals

Renewable energy ⓘProportion of the company's total electricity consumption sourced from renewable sources, expressed as a percentage.
25%2023
Laggard
Market cap ⓘTotal market value of the company's outstanding shares, calculated by multiplying the share price by the number of shares outstanding.
1.7B$, 2026▼7.5% YoY
Revenue ⓘTotal revenue reported in the company's financial statements for the specified reporting year, reflecting income generated from primary business activities. Expressed in millions of USD.
952.0M$, 2025▼8.5% YoY

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
  • Fagron NV, Belgianlisted major compounding pharmacy (pharmacy compounding ingredients), has faced multiple US class actions over alleged inadequate disclosure of US/European compounding pharmacy customer demand normalization following the contested 2024 sustained share price volatility amid postCOVID GLP1 (Ozempic/Wegovy) compounding pharmacy customer demand normalization affecting Belgian institutional shareholders amid US compounding pharmacy regulatory pressure (FDA crackdown).
Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

image report
Available

Sustainability employees

ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.

Total sustainability employees

2-3

ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.

    Available in
    Scale package

    Access
  • Email

  • Email